|
Anticoagulant mechanisms
Citations 21-30 of 73 total displayed.
|
Past content
(since Jan 1999):
|
- Focused Perspectives
Does Heparin Cofactor II Modulate Atherosclerosis and Restenosis?
- Douglas M. Tollefsen
Circulation 2004;109:2682-2684, doi:10.1161/01.CIR.0000130436.14464.FC
[Full text]
- Review: Current Perspective
Bidirectional Relation Between Inflammation and Coagulation
- Marcel Levi, Tom van der Poll, and Harry R. Büller
Circulation 2004;109:2698-2704, doi:10.1161/01.CIR.0000131660.51520.9A
[Full text]
- Brief Rapid Communications
Thrombomodulin and Tissue Factor Pathway Inhibitor in Endocardium of Rapidly Paced Rat Atria
- Takeshi Yamashita, Akiko Sekiguchi, Yu-ki Iwasaki, Kouichi Sagara, Seiji Hatano, Hiroyuki Iinuma, Tadanori Aizawa, and Long-Tai Fu
Circulation 2003;108:2450-2452; published online before print as doi:10.1161/01.CIR.0000102969.09658.F2
[Abstract]
[Full text]
- Articles
Thrombomodulin and Tissue Factor Pathway Inhibitor in Endocardium of Rapidly Paced Rat Atria
- Takeshi Yamashita, Akiko Sekiguchi, Yu-ki Iwasaki, Kouichi Sagara, Seiji Hatano, Hiroyuki Iinuma, Tadanori Aizawa, and Long-Tai Fu
Circulation published November 10, 2003, doi:10.1161/01.CIR.0000102969.09658.F2
[Abstract]
- Brief Rapid Communications
Lack of Adverse Clopidogrel–Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial
- Jacqueline Saw, Steven R. Steinhubl, Peter B. Berger, Dean J. Kereiakes, Victor L. Serebruany, Danielle Brennan, and Eric J. Topol
Circulation 2003;108:921-924; published online before print as doi:10.1161/01.CIR.0000088780.57432.43
[Abstract]
[Full text]
- Articles
Lack of Adverse Clopidogrel-Atorvastatin Clinical Interaction From Secondary Analysis of a Randomized, Placebo-Controlled Clopidogrel Trial
- Jacqueline Saw, Steven R. Steinhubl, Peter B. Berger, Dean J. Kereiakes, Victor L. Serebruany, Danielle Brennan, Eric J. Topol for the Clopidogrel for the Reduction of Events During Observation (CREDO) Investigators
Circulation published August 18, 2003, doi:10.1161/01.CIR.0000088780.57432.43
[Abstract]
- Clinical Investigations and Reports
Relationship of Activated Partial Thromboplastin Time to Coronary Events and Bleeding in Patients With Acute Coronary Syndromes Who Receive Heparin
- Sonia S. Anand, Salim Yusuf, Janice Pogue, Jeffrey S. Ginsberg, and Jack Hirsh
Circulation 2003;107:2884-2888; published online before print as doi:10.1161/01.CIR.0000077530.53367.E9
[Abstract]
[Full text]
- Articles
Relationship of Activated Partial Thromboplastin Time to Coronary Events and Bleeding in Patients With Acute Coronary Syndromes Who Receive Heparin
- Sonia S. Anand, Salim Yusuf, Janice Pogue, Jeffrey S. Ginsberg, Jack Hirsh on Behalf of the Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators
Circulation published June 9, 2003, doi:10.1161/01.CIR.0000077530.53367.E9
[Abstract]
- AHA/ACC Scientific Statement
American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy
- Jack Hirsh, Valentin Fuster, Jack Ansell, and Jonathan L. Halperin
Circulation 2003;107:1692-1711, doi:10.1161/01.CIR.0000063575.17904.4E
[Full text]
- Clinical Investigations and Reports
First Experience With Direct Factor Xa Inhibition in Patients With Stable Coronary Disease: A Pharmacokinetic and Pharmacodynamic Evaluation
- Christopher K. Dyke, Richard C. Becker, Neal S. Kleiman, Judith S. Hochman, Edwin G. Bovill, A. Michael Lincoff, Gary Gerstenblith, Vladimir Dzavik, Laura H. Gardner, Vic Hasselblad, Linda A. Zillman, Yoshimasa Shimoto, Thomas L. Robertson, Satoshi Kunitada, Paul W. Armstrong, and Robert A. Harrington
Circulation 2002;105:2385-2391; published online before print as doi:10.1161/01.CIR.0000016351.12759.52
[Abstract]
[Full text]
|
|
